ABSTRACT
We analyzed the levels of LPO products and antioxidant defense components in women with the metabolic syndrome. Women with the metabolic syndrome had higher values of substrates with unsaturated double bonds and final TBA-reactive substances in comparison with the control group and higher levels of unsaturated double bonds, primary and end products of LPO, and retinol in comparison with the reference group (women with less than 3 signs of metabolic syndrome). No statistically significant differences between the groups were revealed while estimating the coefficient of oxidative stress; however, there was a tendency to an increase in the median value of this parameter in the group with metabolic syndrome. Thus, the results of the study indicate the activity of LPO reactions at different stages in women of reproductive age with the metabolic syndrome, which points to the necessity to evaluate and monitor the content of these metabolites in the patients of this cohort for the purpose of prevention and treatment.
Subject(s)
Metabolic Syndrome , Humans , Female , Lipid Peroxidation , Antioxidants/metabolism , Oxidative Stress , Vitamin AABSTRACT
Activity of some antioxidant enzymes (superoxide dismutase, catalase, and glutathionedependent enzymes), as well as the level of LPO products in the region regional blood flow (collateral branches of the main trunks of ovarian veins) in women with pelvic venous disorders were studied. A compensatory increase in activity of superoxide dismutase, catalase, and glutathione peroxidase during stage I of the disease was found; during stage II, superoxide dismutase activity decreased and glutathione peroxidase increased, while during stage III, pronounced decrease in activities of all studied enzymes was observed. The level of lipid peroxidation products in the regional blood flow increased as the disease progressed, with maximum values in the third stage.
Subject(s)
Catalase/metabolism , Glutathione Peroxidase/metabolism , Glutathione Reductase/metabolism , Glutathione Transferase/metabolism , Phlebitis/enzymology , Superoxide Dismutase/metabolism , Varicose Veins/enzymology , Adult , Case-Control Studies , Female , Humans , Lipid Peroxidation , Middle Aged , Oxidative Stress , Pelvis/blood supply , Pelvis/pathology , Phlebitis/diagnosis , Phlebitis/pathology , Regional Blood Flow , Severity of Illness Index , Varicose Veins/diagnosis , Varicose Veins/pathologyABSTRACT
Polycystic ovary syndrome (PCOS) is the most common cause of female endocrine infertility. Insulin resistanÑе is supposed to be one of the essential factors of this disease pathways. At the same time, the mechanisms of PCOS development in insulin-resistant patients have not been completely established. Leptin and Peroxisome Proliferator-Activated Receptor γ(PPARγ) are involved in carbohydrate metabolism and reproduction function regulation. It indicates that leptin and PPARγ possibly play a role in the pathways of PCOS. This article is a review of publications on this issue. The purpose of this review was to systematize the available information on the molecular mechanisms that determine the role of leptin and PPARγ in the development of PCOS. The literature search was carried out from 04/05/2020 to 05/17/2020 using the scientific literature databases: NCBI PubMed (foreign sources) and Cyberleninka (domestic sources). We analyzed publications for the period 1990-2020.The review presents the current understanding of the possible role of leptin and PPARγ in the regulation of endocrine, immune systems, and reproductive function, as well as in the development of PCOS. Currently, no studies cover the mechanisms of interaction between leptin and PPARγ in the pathways of this syndrome. The available studies indicating the individual contribution and association of leptin and PPARγ with PCOS are conflicting and have many limitations. Therefore, more studies of direct and indirect interaction of leptin and PPARγ, as well as their role in PCOS pathways, are needed.
Subject(s)
Infertility, Female , Insulin Resistance , Polycystic Ovary Syndrome , Female , Humans , Leptin , PPAR gamma/geneticsABSTRACT
AIM: To assess quantitative characteristics of sleep in perimenopausal women treated with melatonin in a dose of 3 mg during 3 month. MATERIAL AND METHODS: A study included 21 perimenopausal women with sleep disorders. Seventeen women completed the study. Insomnia Severity Index (ISI), anamnestic and gynecological examinations, polysomnographic monitoring (PSM) were used. All patients received melatonin (melaxen) 30 min before going to bed in a dose of 3 mg daily during 3 month. RESULTS: Insomnia was confirmed by PSM. The dynamics of PSM demonstrated the improvement of the latency to sleep onset, total sleep efficiency and increase in percentage of REM-sleep. A significant number of EEG activation responses showed a decrease in sleep fragmentation and improvement of the structure of sleep segments. CONCLUSION: The use of melatonin drugs, including melaxen in a dose of 3 mg during 3 month, is one of the main methods of treatment of sleep disorders in age-related estrogen deficiency. The main clinical effect was due to the elimination of pre- and intrasomnic disorders.
Subject(s)
Estrogens/deficiency , Melatonin/administration & dosage , Sleep Initiation and Maintenance Disorders/drug therapy , Sleep Wake Disorders/drug therapy , Electroencephalography , Female , Humans , Middle Aged , Polysomnography , Sleep Initiation and Maintenance Disorders/diagnosis , Sleep Wake Disorders/diagnosis , Sleep, REMABSTRACT
Specific features of LPO processes and antioxidant defense were studied in patients with polycystic ovarian syndrome (PCOS) and infertility. Changes in LPO processes in patients with PCOS were compensatory, which manifested in increased α-tocopherol and retinol concentrations and moderate decrease in superoxide dismutase activity. Intensification of prooxidant processes was found in the group of patients with infertility without PCOS. The observed changes necessitate differentiated approach to the treatment of these patients.
